SEARCH · Search PubMed

Results for “CHROMIUM”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

SourceResearch connectionFrom yearThrough year

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 523 records · Page 29Linked to original sources

PubMed1985

Determination of total and hexavalent chromium in bile after intravenous administration of potassium dichromate in rats.

Total and hexavalent chromium were measured in bile samples obtained from cannulated bile ducts of male rats iv administered with potassium dichromate at various doses corresponding to 0.1, 0.5, and 1 mg of chromium. The evaluation of the hexavalent form was performed by separation with a liquid anion exchanger and electrothermal atomization-atomic absorption spectrophotometric determination. Within 2 hr 1.35-2.23% of the chromium injected was recovered in bile as total chromium, the hexavalent form accounting for less than 1% of the total chromium collected, which seems almost entirely excreted as trivalent chromium. Since Cr(VI) administered iv was quickly reduced to Cr(III) in blood, the possibility exists for chromium in trivalent form to penetrate into the liver cells and to be excreted in the bile, possibly by binding to a carrier such as the low-molecular-weight substance described by Yamamoto et al. (A. Yamamoto, O. Wada, and T. Ono, Toxicol. Appl. Pharmacol. 59, 515, 1981).

Animals↗

PubMed1983

Determination of chromium in human milk, serum and urine by electrothermal atomic absorption spectrometry without preliminary ashing.

In the present study a Perkin-Elmer 5000 atomic absorption spectrometer equipped with a tungsten--iodide lamp for improved background correction at the 357.9 nm chromium absorption line and an HGA 500 graphite furnace were employed for the direct determination of chromium in human serum, milk and urine. The method of standard additions was used: 0.25-0.75 ng Cr was added to 1 ml samples. Except for urine samples, a dilution of 1 + 1 to 1 + 2 with H2O was necessary in order to obtain correct calibration curves. The average concentration of chromium in all the samples of normal subjects was less than 0.5 ng Cr ml-1. The day-to-day variation for all of the pooled samples was around 10% (relative standard deviation). For urine, the accuracy of the method was tested by comparing the results of another laboratory for the same two round robin samples. Excellent agreement was found between the present method and those of the other laboratory that had used isotope dilution--mass spectrometry and continuum source wavelength modulated echelle--atomic absorption spectrometry to define the chromium concentration in the samples. The detection limit of the method, 0.05 ng Cr ml-1 for urine and serum and 0.1 ng Cr ml-1 for human milk, was sufficient for the biological fluids analyzed. The method was employed for the determination of chromium in 24-h urine samples of maturity onset diabetics supplemented with 20 or 200 micrograms Cr3+ d-1 for six weeks. It was shown that the 24-h urinary chromium excretion accurately indicates the daily dietary chromium intake of these patients.

Adult↗

PubMed1989

Nutritional chemistry of chromium.

There has been considerable progress in understanding the role of chromium in human nutrition. However, the lack of data on the forms of chromium-absorption from foods by the gastro-intestinal tract, and our concomitant inability to obtain an accurate assessment of the daily mobile pool of metabolically active chromium in the human body continues to be an impediment in assessing the overall impact of chromium nutrition. Based on recent chromium data on human tissues and body fluids available in the literature, an assessment of chromium content in different body compartments as well as in the total body is presented. However, on the analytical side, a few problems still persist and, therefore, a reliable analysis for chromium is restricted to a few selected laboratories.

Animals↗

PubMed1989

Chromium carcinogenicity: California strategies.

Hexavalent chromium was identified by California as a toxic air contaminant (TAC) in January 1986. The California Department of Health Services (CDHS) concurred with the findings of the International Agency for Research on Cancer that there is sufficient evidence to demonstrate the carcinogenicity of chromium in both animals and humans. CDHS did not find any compelling evidence demonstrating the existence of a threshold with respect to chromium carcinogenesis. Experimental data was judged inadequate to assess potential human reproductive risks from ambient exposures. Other health effects were not expected to occur at ambient levels. The theoretically increased lifetime carcinogenic risk from a continuous lifetime exposure to hexavalent chromium fell within the range 12-146 cancer cases per nanogram hexavalent chromium per cubic meter of air per million people exposed, depending on the potency estimate used. The primary sources found to contribute significantly to the risk of exposure were chrome platers, chromic acid anodizing facilities and cooling towers utilizing hexavalent chromium as a corrosion inhibitor. Evaluation of genotoxicity data, animal studies and epidemiological studies indicates that further consideration should be given to the potential carcinogenicity of hexavalent chromium via the oral route.

Air Pollutants↗

PubMed1990

An oxygen dependence in chromium mutagenesis.

Evidence is provided that mutagenicity in Salmonella by a chromium(VI) salt and a chromium(III) compound has a differential dependence on the presence of oxygen. The mutagenic chromium(III) compound, cis-dichlorobis(2,2'-bipyridyl)chromium(III), reverted Salmonella strains, TA102 and TA2638, only under aerobic conditions. Potassium dichromate (chromium VI) required the presence of oxygen to revert the Salmonella strain TA102 but induced a moderate reversion frequency in TA2638 under anaerobic conditions. The data also support a role for oxygen radicals in chromium-mediated mutagenesis and suggests at least two pathways by which chromium compounds can induce mutations.

2,2'-Dipyridyl↗

PubMed1993

Biodegradation of orthodontic appliances. Part I. Biodegradation of nickel and chromium in vitro.

The purpose of this study is to compare in vitro the corrosion rate of a standard orthodontic appliance consisting of bands, brackets and either stainless steel or nickel-titanium arch wires. The corrosion products analyzed were nickel and chromium. Evaluation was conducted with the appliances immersed for 4 weeks in a prepared artificial saliva medium at 37 degrees C. Ten identical sets were used, each simulating a complete orthodontic appliance used on a maxillary arch with a full complement of teeth. Five sets were ligated to stainless steel arch wires, and the other five sets were ligated to nickel-titanium arch wires. Nickel and chromium release was quantified with the use of a flameless atomic absorption spectrophotometry. The analysis of variance was used to determine if differences existed between the nickel and chromium release according to arch wire type, as well as with time (days 1, 7, 14, 21, and 28). The results indicate that (1) orthodontic appliances release measurable amounts of nickel and chromium when placed in an artificial saliva medium. (2) The nickel release reaches a maximum after approximately 1 week, then the rate of release diminishes with time. On the other hand, chromium release increases during the first 2 weeks and levels off during the subsequent 2 weeks. (3) The release rates of nickel or chromium from stainless steel and nickel-titanium arch wires are not significantly different. (4) For both arch wire types, the release for nickel averaged 37 times greater than that for chromium. How much of these corrosive products are actually absorbed by patients still needs to be determined.

Alloys↗

PubMed2006

Chromium and vanadate combination increases insulin-induced glucose uptake by 3T3-L1 adipocytes.

Insulin activates signaling pathways in target tissues through the insulin receptor and Tyr phosphorylation of intracellular proteins. Vanadate mimics insulin and enhances its actions through inhibition of protein Tyr phosphatases. Chromium is a micronutrient that enhances insulin action to normalize blood glucose, but the mechanism is not understood. Here we show that either vanadate or chromium stimulates Tyr phosphorylation of insulin receptor in mouse 3T3-L1 adipocytes compared to insulin alone, but a combination of vanadate and chromium is not additive. Phosphorylation of MAPK or 4E-BP1 as markers for insulin signaling is stimulated by vanadate plus insulin, and chromium does not enhance the effects. Vanadate robustly activates glucose uptake by 3T3-L1 adipocytes even without added insulin and increases insulin-stimulated glucose uptake. Chromium pretreatment of adipocytes slightly enhances glucose uptake in response to insulin, but significantly increases glucose uptake above that induced by insulin plus vanadate. These data show that chromium enhances glucose uptake even when Tyr phosphorylation levels are elevated by vanadate plus insulin, suggesting separate mechanisms of action for vanadate and chromium.

3T3-L1 Cells↗

PubMed2005

Preliminary studies on continuous chromium(VI) biological removal from wastewater by anaerobic-aerobic activated sludge process.

The long-term continuous chromium(VI) removal from synthetic wastewater affected by influent hexavalent chromium (Cr(VI)) and glucose concentrations were studied with an anaerobic-aerobic activated sludge process. It was observed that before activated sludge was acclimated, the chromium in the effluent increased immediately as the influent chromium increased. However, both Cr(VI) and total chromium (TCr) in the effluent significantly decreased after acclimation. In the acclimated activated sludge, the chromium removal efficiency was 100% Cr(VI) and 98.56% TCr at influent Cr(VI) levels of 20 mg/day, 100% Cr(VI) and 98.92% TCr at influent Cr(VI) levels of 40 mg/day, and 98.64% Cr(VI) and 97.16% TCr at influent Cr(VI) levels of 60 mg/day. The corresponding effluent Cr(VI) and TCr concentrations were 0 and 0.012 mg/l, 0 and 0.018 mg/l, and 0.034 mg/l and 0.071 mg/l, respectively. When the influent glucose increased from 1125 to 1500 mg/l at influent Cr(VI) dosage of 60 mg/day, the Cr(VI) and TCr removal efficiency with the acclimated activated sludge improved from 98.64% and 97.16% to 100% and 98.48%, respectively, and the chromium concentration in the effluent decreased from 0.034 mg/l of Cr(VI) and 0.071 mg/l of TCr to 0 (Cr(VI)) and 0.038 mg/l (TCr). The effluent COD and turbidity was around 40 mg/l and 0, respectively, after the activated sludge was acclimated. Further studies showed that after the activated sludge was acclimated, its specific dehydrogenases activity (SDA) and protein contents increased. The SDA and protein increased respectively 15% and 10% when influent Cr(VI) increased from 20 to 60 mg/day.

Bioreactors↗

PubMed2006

Adsorption of chromium(VI) on low cost adsorbents derived from agricultural waste material: a comparative study.

Two low cost adsorbents were prepared by using groundnut husk and were tested for the removal of chromium. All the experiments were carried out in batch process with chromium spiked samples of drinking water. Silver impregnated groundnut husk carbon and groundnut husk carbon were tested for the removal of chromium(VI). Effects of adsorbent quantity, pH, contact time and agitation rate were investigated on removal of chromium. The adsorption data were fitted well by Freundlich adsorption isotherm. Approximately, 97% of hexavalent chromium was removed at pH 3 within 5h. It was found that adsorbents chemically modified with an oxidizing agent demonstrated better chromium removal capabilities as compared to pure adsorbents in terms of their adsorption rate. On the basis of present studies, it can be concluded that groundnut husk carbon oxidized with silver treatment, has a higher chromium adsorption capacities.

Adsorption↗

PubMed2004

Chromium-yeast supplementation of chicken broilers in an industrial farming system.

The experiment was performed on ISA broilers at big farm conditions. One day old chickens were randomly assigned to two poultry-houses with the capacity of 10600 birds each. Chromium was provided in the form of chromium enriched yeast (1.0 g Cr/kg yeast) given in doses of 0.2 mg Cr/kg diet. No significant differences in growth rate and only a slight decrease of feed conversion ratio was found in broilers receiving chromium-yeast supplement. However, these birds had a lower mortality rate comparied with the rate observed in the controls. Moreover, dietary chromium led also to an improvement of carcass composition. Organic chromium supplementation increased the weight of pectoral muscles and meat of these broilers contained less amounts of fat and cholesterol. These effects were accompanied by an insignificant increase of chromium concentration in the pectoral muscles of birds fed chromium supplemented diets, from 40 to 52 microg/kg wet tissue.

Animal Feed↗

PubMed2006

Hypoglycemic potency of novel trivalent chromium in hyperglycemic insulin-deficient rats.

Two sources of chromium III, "chromium 454" and "chromium picolinate," were tested in insulin-deficient Streptozocin-treated diabetic rats. This model was selected in order to evaluate the possibility of any hypoglycemic potency of chromium in a relative absence of blood insulin concentration. Three weeks of the treatment with CRC454 and CrP resulted in a 38% and 11% reduction of blood glucose levels, respectively. Body weight gains were equally improved by both treatments. Blood levels of CK, ALT and AST were significantly reduced by CRC454 and CrP. These results might suggest that any hypoglycemic effect of trivalent chromium under insulin-deficient conditions could be largely dependent upon the type of chromium agent and associated characteristics such as solubility and bioavalibility. In contrast, improvement of body weight gains and blood levels of CK, AST and ALT seems to be less dependent on the type of chromium compound under these experimental conditions. In conclusion, CRC454 showed significant reduction of hyperglycemia under insulin-deficient conditions.

Alanine Transaminase↗

PubMed2006

The influence of chromium chloride-containing milk to glycemic control of patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial.

The aim of this study is to evaluate the effect and safety of chromium-containing milk powder in patients with type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial was conducted in Taiwan. A total of 60 patients with type 2 diabetes mellitus, aged 30 to 75 years, and on a dose of gliclazide sulfonylurea agent (< or =160 mg/d) for at least 3 months were enrolled. Their glycosylated hemoglobin ranged from 7.5% to 12%, fasting plasma glucose (FPG) from 140 to 250 mg/dL, and body mass index from 20 to 35 kg/m(2). The subjects were divided into 2 groups, one group to receive chromium-containing milk powder (chromium 200 microg/20 g milk powder) and the other to receive placebo twice a day for 16 weeks. Frequently sampled intravenous glucose tolerance test (IVGTT) was performed before and after treatment. The chromium group demonstrated a lower FPG and fasting insulin (-38.1 +/- 9.2 vs 63 +/- 8. 5 mg/dL and -1.7 +/- 0.2 vs 1.9 +/- 0.3 microU/mL, respectively; P < .05), especially in male patients (-41 +/- 9.2 vs 85 +/- 11.7 mg/dL and -2.7 +/- 0.2 vs 3.1 +/- 0.3 microU/mL, respectively; P < .01), at the end of the study. Lower glycosylated hemoglobin was observed in chromium-treated male patients (-1.1 +/- 0. 5 vs 0.7 +/- 0. 2; P < .05). However, there were no significant changes in other metabolic parameters (lipid profiles including total cholesterol, triglyceride, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol), except improvement of insulin resistance (homeostasis model assessment for insulin resistance and insulin sensitivity index from frequently sampled intravenous glucose tolerance test) observed in male patients (-2.1 +/- 1.1 vs -0.41 +/- 1.12 and 0.18 +/- 0.11 vs -0.15 +/- 0. 2, respectively; P < .05). There were no adverse events in both groups, except for mild complaints in the chromium group on constipation (5%) and flatulence (5%). Intake of milk powder containing 400 microg/d of chromium for 16 weeks in subjects with type 2 diabetes mellitus resulted in lowering of FPG, fasting insulin, and improvement of metabolic control in male patients.

Animals↗

PubMed2006

Oral chromium(VI) does not affect the frequency of micronuclei in hematopoietic cells of adult mice and of transplacentally exposed fetuses.

Chromium(VI) compounds are genotoxic in a variety of cellular systems. Their potential carcinogenicity is affected by toxicokinetic patterns restricting bioavailability to certain targets, and by metabolic pathways affecting interaction of chromate-derived reactive species with DNA. Epidemiological data indicate that chromium(VI) can be carcinogenic to the human respiratory tract following inhalation at doses that are only achieved in certain occupational settings. However, concern has been raised that adverse effects may also result from oral intake. In order to further explore this issue, we performed studies in BDF1 and Swiss mice of both genders and various age. Sodium dichromate dihydrate and potassium dichromate were administered either with the drinking water, up to a concentration of 500 mg chromium(VI)/l for up to 210 consecutive days, or in a single intragastric dose of 17.7 mg/kg body weight. Under these conditions, no increase of the micronucleus frequency was observed in either bone marrow or peripheral blood erythrocytes. Conversely, the same compounds induced a clastogenic damage following intraperitoneal injection, which by-passes detoxification mechanisms. In addition, due to the hypothesis that susceptibility may be increased during the period of embryogenesis, we treated pregnant mice, up to a concentration of 10mg chromium(VI)/l drinking water. There was no effect on the numbers of fetuses/dam and on body weight of fetuses. Again, no toxic or genotoxic effect was observed either in bone marrow of pregnant mice or in liver and peripheral blood of their fetuses. Thus, even at doses that largely exceed drinking water standards (up to 10,000 times) or by massive intragastric administration, chromium(VI) is not genotoxic to hematopoietic cells of either adult mice or transplacentally exposed fetuses. These conclusions are consistent with the poor toxicity and lack of carcinogenicity of oral chromium(VI), and are mechanistically explained by the high efficiency of chromium(VI) detoxification processes in the gastrointestinal tract.

Administration, Oral↗

PubMed2007

Mobilization and speciation of chromium in compost: a methodological approach.

An integral approach to study the mobility of chromium in compost is presented. The approach is based on batch pH dependence leaching tests and the analysis of the leachates for total chromium, chromium(VI) and complexes of chromium(III) with natural organic matter. As leachings are performed with no aggressive reagents (ultrapure water with added nitric acid or potassium hydroxide), the method can be considered a good approach to simulate natural scenarios. The analysis of leachates is complemented with the determination of total chromium and total Cr(VI) in the solid sample. Speciation analysis are done by high performance liquid chromatography with inductively coupled plasma mass spectrometry as detection technique; Cr(VI) is determined by ion chromatography, whereas Cr(III) complexes with natural organic matter by size exclusion chromatography. In the compost studied, Cr(VI) accounted for 6% of the total chromium in the solid, whereas no significant amounts of Cr(VI) were mobilized in the pH range studied (4-10). Chromium is mobilized as Cr(III) bound to organic matter, both to humic and fulvic acids, with an increasing contribution of humic acids at higher pHs.

Benzopyrans↗

PubMed2002

Removal of chromium(VI) from aqueous solutions by polymer inclusion membranes.

The transport through polymer inclusion membranes (PIMs) was found as the effective and selective method of chromium(VI) anions removal from chloride acidic aqueous solutions. The optimal PIMs content was as follows: 41 wt% of cellulose triacetate as the support, 23 wt% of tri-n-octylamine as the ionic carrier, and 36 wt% of o-nitrophenyl pentyl ether as the plasticizer. The results obtained show a linear decrease of permeability coefficient and initial flux values with source phase pH increase. Also linear decrease of initial flux in log-log scale with chromium(VI) concentration increase was observed. Value of slope of this relationship was found to be 0.96 which indicates a first order of chromium(VI) reaction with tri-n-octylamine at membrane/aqueous source interface. Transport of chromium(VI) through PIMs reduces the concentration of chromium(VI) in source aqueous phase from 1.0 to 0.0028 ppm, which is below permissible limit in drinking water in Poland. Competitive transport of chromium(VI), cadmium(II), zinc(II), and iron(III) from acidic aqueous solution across PIMs was found to be efficient for chromium(VI) (99%), and cadmium(II) (99%).

Carcinogens, Environmental↗

PubMed1998

Chromium in the environment of Finland.

This paper focuses upon the use, import and release of chromium to the environment of Finland. In addition, the behavior of trivalent and hexavalent chromium in soils has been briefly reviewed. In Finland, consumption of chromium compounds occurs in the following pattern: stainless steel > leather tanning > metal plating > chemicals. The emission of chromium has decreased from 114 t in 1979 to 28 t in 1995. The highest release of chromium continues to be from ferrochromium and stainless steel plants. From these facilities, 85% of slag and dusts are used by a secondary facility to recover valuable metal. In the industrial areas, the oxidizing behavior of chromium (III) is still unknown. In this study, the leachability of chromium (VI) to ground water and its effects on terrestrial and aquatic species in Finland are discussed.

Chromium↗

PubMed2001

Removal of chromium from water and wastewater by ion exchange resins.

Removal of chromium from water and wastewater is obligatory in order to avoid water pollution. Batch shaking adsorption experiments were carried out to evaluate the performance of IRN77 and SKN1 cation exchange resins in the removal of chromium from aqueous solutions. The percentage removal of chromium was examined by varying experimental conditions viz., dosage of adsorbent, pH of the solution and contact time. It was found that more than 95% removal was achieved under optimal conditions. The adsorption capacity (k) for chromium calculated from the Freundlich adsorption isotherm was found to be 35.38 and 46.34 mg/g for IRN77 and SKN1 resins, respectively. The adsorption of chromium on these cation exchange resins follows the first-order reversible kinetics. The ion exchange resins investigated in this study showed reversible uptake of chromium and, thus, have good application potential for the removal/recovery of chromium from aqueous solutions.

Adsorption↗

PubMed1999

Chromium(III) hydrolytic oligomers: their relevance to protein binding.

The nature of chromium(III) complexes has been found to show a profound influence in its interaction with collagen. The hydrothermal stability of rat tail tendon (RTT) fibres treated with dimeric, trimeric and tetrameric species of chromium(III) has been found to be 102, 87 and 68 degrees C, while that of native RTT is 62 degrees C. This shows that the efficiency of crosslinking of collagen by chromium(III) species is dimeric > trimeric > tetrameric. This order of stabilisation is again confirmed by cyanogen bromide (CNBr) cleavage of RTT collagen treated with dimeric, trimeric and tetrameric chromium(III) species. CNBr has been found to cleave the collagen treated with tetrameric chromium(III) species extensively. On the other hand, dimer-treated collagen does not undergo any cleavage on CNBr treatment. The equilibrium constants for the reaction of a nucleophile like NCS(-) to the dimeric, trimeric and tetrameric species of chromium(III) have been found to be 15.7+/-0.1, 14.6+/-0.1 and 1.2+/-0.1 M(-1), respectively. These equilibrium constant values reflect the relative thermodynamic stability of the chromium(III) species-nucleophile complex. The low stabilising effect of the tetrameric species can be traced to its low thermodynamic affinity for nucleophiles.

Animals↗